DeepMed Research

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Phase 2

Recruiting

Conditions: Functioning Lung Neuroendocrine Tumor
Advanced Lung Neuroendocrine Tumor
Lung Neuroendocrine Neoplasm
Lung Neuroendocrine Tumor G1
Unresectable Lung Neuroendocrine Tumor
Unresectable Lung Neuroendocrine Neoplasm
Locally Advanced Lung Neuroendocrine Neoplasm
Lung Neuroendocrine Tumor G2
Recurrent Lung Neuroendocrine Neoplasm
Metastatic Lung Neuroendocrine Neoplasm

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Other: Fludeoxyglucose F-18
Drug: Everolimus
Drug: Lutetium Lu 177 Dotatate
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Procedure: Single Photon Emission Computed Tomography
Other: Survey Administration

First Posted Date: 2020-12-14

Last Posted Date: 2025-04-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT04665739

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Tower Cancer Research Foundation, Beverly Hills, California, United States
🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States

and more 24 locations

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome

Phase 1

Active, not recruiting

Conditions: Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8
Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Duvelisib
Biological: Nivolumab
Procedure: Positron Emission Tomography
Procedure: Punch Biopsy

First Posted Date: 2020-12-04

Last Posted Date: 2025-03-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 38

Registration Number: NCT04652960

Locations: 🇺🇸
UCHealth University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸
UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States

and more 14 locations

Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies

Phase 1

Withdrawn

Conditions: Sarcomas
Melanomas
Germ Cell Tumors
Epithelial Malignancies (Excluding Lung and Renal Cell Carcinomas)
Pulmonary Metastases

Interventions: Device: AeroEclipse II Breath Actuated Nebulizer
Drug: Bintrafusp alfa
Drug: Azacytidine

First Posted Date: 2020-12-02

Last Posted Date: 2021-12-17

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT04648826

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

Phase 1

Recruiting

Conditions: Biliary Tract Malignancy
Bile Duct Neoplasm
Cholangiocarcinoma

Interventions: Drug: Tivozanib

First Posted Date: 2020-11-27

Last Posted Date: 2025-05-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 31

Registration Number: NCT04645160

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma

Phase 1

Withdrawn

Conditions: Adult T-cell Leukemia/Lymphoma
Extranodal NK-/T-cell Lymphoma, Nasal Type
Enteropathy-Associated T-Cell Lymphoma
Monomorphic Epiteliotrophic Intestinal T-cell Lymphoma
Hepatosplenic T-cell Lymphoma

Interventions: Drug: CC-486 (5-azacitidine)
Drug: Duvelisib
Drug: Romidepsin
Drug: Doxorubicin

First Posted Date: 2020-11-23

Last Posted Date: 2022-11-04

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT04639843

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

Phase 1

Recruiting

Conditions: Recurrent Ovarian High Grade Serous Adenocarcinoma
Recurrent Platinum-Resistant Ovarian Carcinoma

Interventions: Drug: Abemaciclib
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Drug: Olaparib

First Posted Date: 2020-11-18

Last Posted Date: 2025-04-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT04633239

Locations: 🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸
UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
🇺🇸
UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States

and more 20 locations

M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer

Phase 1

Recruiting

Conditions: Cancer Of Prostate
Prostate Neoplasms

Interventions: Drug: ADT
Drug: Prednisone
Drug: Docetaxel
Drug: M7824
Drug: M9241

First Posted Date: 2020-11-18

Last Posted Date: 2025-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 86

Registration Number: NCT04633252

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread

Phase 1

Completed

Conditions: Extensive Stage Lung Small Cell Carcinoma
Malignant Solid Neoplasm
Metastatic Malignant Neoplasm in the Brain

Interventions: Biological: Atezolizumab
Drug: Carboplatin
Drug: Entinostat
Drug: Etoposide

First Posted Date: 2020-11-17

Last Posted Date: 2023-10-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3

Registration Number: NCT04631029

Locations: 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
University of Virginia Cancer Center, Charlottesville, Virginia, United States

and more 2 locations

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Phase 2

Recruiting

Conditions: Renal Pelvis and Ureter Urothelial Carcinoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Drug: Cisplatin
Procedure: Computed Tomography
Drug: Doxorubicin Hydrochloride
Drug: Gemcitabine Hydrochloride
Biological: Durvalumab
Procedure: Magnetic Resonance Imaging
Drug: Methotrexate
Biological: Pegfilgrastim
Procedure: Therapeutic Conventional Surgery
Drug: Vinblastine Sulfate

First Posted Date: 2020-11-16

Last Posted Date: 2025-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 249

Registration Number: NCT04628767

Locations: 🇺🇸
Kingman Regional Medical Center, Kingman, Arizona, United States
🇺🇸
Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

and more 251 locations

Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones

Phase 2

Terminated

Conditions: Metastatic Malignant Neoplasm in the Bone
Stage IVB Prostate Cancer AJCC v8
Castration-Resistant Prostate Carcinoma
Metastatic Prostate Adenocarcinoma
Stage IV Prostate Cancer AJCC v8
Stage IVA Prostate Cancer AJCC v8

Interventions: Other: Questionnaire Administration
Radiation: Tin Sn 117m Pentetate

First Posted Date: 2020-11-05

Last Posted Date: 2024-04-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1

Registration Number: NCT04616547

Locations: 🇺🇸
University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy